These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 22027694

  • 1. Identification of docetaxel resistance genes in castration-resistant prostate cancer.
    Marín-Aguilera M, Codony-Servat J, Kalko SG, Fernández PL, Bermudo R, Buxo E, Ribal MJ, Gascón P, Mellado B.
    Mol Cancer Ther; 2012 Feb; 11(2):329-39. PubMed ID: 22027694
    [Abstract] [Full Text] [Related]

  • 2. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
    Codony-Servat J, Marín-Aguilera M, Visa L, García-Albéniz X, Pineda E, Fernández PL, Filella X, Gascón P, Mellado B.
    Prostate; 2013 Apr; 73(5):512-21. PubMed ID: 23038213
    [Abstract] [Full Text] [Related]

  • 3. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
    Marín-Aguilera M, Codony-Servat J, Reig Ò, Lozano JJ, Fernández PL, Pereira MV, Jiménez N, Donovan M, Puig P, Mengual L, Bermudo R, Font A, Gallardo E, Ribal MJ, Alcaraz A, Gascón P, Mellado B.
    Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
    [Abstract] [Full Text] [Related]

  • 4. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M, Kashiwagi E, Yokomizo A, Takeuchi A, Dejima T, Song Y, Tatsugami K, Inokuchi J, Uchiumi T, Naito S.
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [Abstract] [Full Text] [Related]

  • 5. Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.
    Desarnaud F, Geck P, Parkin C, Carpinito G, Makarovskiy AN.
    Cancer Biol Ther; 2011 Jan 15; 11(2):204-12. PubMed ID: 21057205
    [Abstract] [Full Text] [Related]

  • 6. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
    Kato T, Mizutani K, Kameyama K, Kawakami K, Fujita Y, Nakane K, Kanimoto Y, Ehara H, Ito H, Seishima M, Deguchi T, Ito M.
    Urol Oncol; 2015 Sep 15; 33(9):385.e15-20. PubMed ID: 26027763
    [Abstract] [Full Text] [Related]

  • 7. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
    Crea F, Duhagon Serrat MA, Hurt EM, Thomas SB, Danesi R, Farrar WL.
    Int J Cancer; 2011 Apr 15; 128(8):1946-54. PubMed ID: 20568112
    [Abstract] [Full Text] [Related]

  • 8. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
    Lundon DJ, Boland A, Prencipe M, Hurley G, O'Neill A, Kay E, Aherne ST, Doolan P, Madden SF, Clynes M, Morrissey C, Fitzpatrick JM, Watson RW.
    BMC Cancer; 2017 Mar 01; 17(1):163. PubMed ID: 28249598
    [Abstract] [Full Text] [Related]

  • 9. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.
    O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, Rani S, O'Driscoll L, Fitzpatrick JM, Watson RW.
    Mol Cancer; 2011 Oct 07; 10():126. PubMed ID: 21982118
    [Abstract] [Full Text] [Related]

  • 10. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
    Ploussard G, Terry S, Maillé P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, Salomon L, Culine S, Buttyan R, Vacherot F, de la Taille A.
    Cancer Res; 2010 Nov 15; 70(22):9253-64. PubMed ID: 21045157
    [Abstract] [Full Text] [Related]

  • 11. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
    Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, You M, Wang L.
    Mol Cancer; 2016 Nov 10; 15(1):70. PubMed ID: 27832783
    [Abstract] [Full Text] [Related]

  • 12. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.
    Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Boyer MJ, Stockler MR, Pavlakis N, Marx G, Mallesara G, Gurney H, Clark SJ, Swarbrick A, Daly RJ, Horvath LG.
    Br J Cancer; 2014 May 13; 110(10):2462-71. PubMed ID: 24714754
    [Abstract] [Full Text] [Related]

  • 13. KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer.
    Sekino Y, Oue N, Shigematsu Y, Ishikawa A, Sakamoto N, Sentani K, Teishima J, Matsubara A, Yasui W.
    Urol Oncol; 2017 Jan 13; 35(1):31.e13-31.e20. PubMed ID: 27665358
    [Abstract] [Full Text] [Related]

  • 14. The role of testicular nuclear receptor 4 in chemo-resistance of docetaxel in castration-resistant prostate cancer.
    Chen B, Yu S, Ding X, Jing C, Xia L, Wang M, Matro E, Rehman F, Niu Y, Li G, Chang C.
    Cancer Gene Ther; 2014 Oct 13; 21(10):411-5. PubMed ID: 25104727
    [Abstract] [Full Text] [Related]

  • 15. Identification of lipidomic profiles associated with drug-resistant prostate cancer cells.
    Ingram LM, Finnerty MC, Mansoura M, Chou CW, Cummings BS.
    Lipids Health Dis; 2021 Feb 17; 20(1):15. PubMed ID: 33596934
    [Abstract] [Full Text] [Related]

  • 16. The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance.
    Bascetta L, Oliviero A, D'Aurizio R, Evangelista M, Mercatanti A, Pellegrini M, Marrocolo F, Bracarda S, Rizzo M.
    Int J Mol Sci; 2017 Jul 13; 18(7):. PubMed ID: 28703747
    [Abstract] [Full Text] [Related]

  • 17. Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3.
    Hu F, Zhao Y, Yu Y, Fang JM, Cui R, Liu ZQ, Guo XL, Xu Q.
    Cancer Lett; 2018 Mar 01; 416():24-30. PubMed ID: 29246644
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.
    Altavilla A, Iacovelli R, Procopio G, Alesini D, Risi E, Campennì GM, Palazzo A, Cortesi E.
    Cancer Biol Ther; 2012 Sep 01; 13(11):1001-8. PubMed ID: 22825325
    [Abstract] [Full Text] [Related]

  • 20. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL, Overman MJ, Petrofski JA, Campbell PA, de Marzo AM, Nelson WG.
    Int J Oncol; 2000 Dec 01; 17(6):1077-86. PubMed ID: 11078791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.